EVALUATING THE OCCURRENCE OF ADVERSE EVENTS AMONG PEDIATRIC PATIENTS EXPOSED TO INTRAVENOUS LACOSAMIDE (VIMPAT®) USING REAL WORLD DATA

30/01/2020
02/07/2024
EU PAS number:
EUPAS32597
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

Study-protocol amd1_redacted

English (2.38 MB - PDF) View document
Study results
Study results

ep0147-bodytext-redacted

English (1.65 MB - PDF) View document
Study report
Other information